Mechanistic studies revealed pathway-specific modulation, with anti-radiodermatitis effects primarily mediated by inhibition of MAPK/PI3K-AKT phosphorylation rather than the NF-κB pathway. The gene discussed is NFKB1; the disease is radiodermatitis.